Druck Icon

Eckert & Ziegler AG: Strong Second Quarter

Berlin, August 9, 2005. Eckert & Ziegler AG (ISIN DE0005659700), a Berlin-based specialist for radiation related products for the diagnosis and treatment of cancer, posted its best second-quarter result since being listed on the stock exchange with sales of 10.2 million EUR. This represents an increase of around 17% over what was also a strong second quarter in 2004, but unlike last year, it has not been affected by the accounts for production systems.

On the profit side, the result before income tax and minority interest rose by about 73% over the first half of 2004, from 0.9 to 1.5 million EUR. Earnings per share from continuing operations amounted to 0.25 EUR. The EPS of the last years period contained a special effect of TEUR 1,191 net from the deconsolidation of NEMOD. Without taking into account this special effect the EPS showed an increase of 94%. Net income from continuing operations after taxes nearly doubled from 0.4 million EUR to 0.8 million EUR.

The Therapy segment showed the greatest growth in sales, from 6.9 million EUR last year to 8.2 million EUR this year, representing an increase of 18%. The Nuclear Medicine and Industry segment posted a somewhat more modest increase of 8% (10.6 million EUR compared to last year's 9.8 million), due in part to the need to compensate in that segment for the dollar exchange rate, which was about 4% less favourable than last year.

For the financial year 2005 the Board continues to expects sales of approximately 40 million EUR and an earning per share between 0,50 and 0,80 EUR. The complete quarterly report II/2005 can be viewed at www.ezag.de.

The Board of Directors